Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Expression of TLR2 and TLR4 in the Lung of Chronic Obstructive Pulmonary Disease (COPD) Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by Seoul National University Bundang Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Seoul National University Bundang Hospital
ClinicalTrials.gov Identifier:
NCT01226199
First received: October 21, 2010
Last updated: June 7, 2011
Last verified: June 2011
  Purpose

Smoking is the most important risk factor of COPD, but only a fourth of smokers had COPD in their life. There are also healthy smokers without evidence of COPD. Investigators hypothesize that innate immunity may affect this difference between COPD patients and healthy smokers, because TLR4 is the receptor of LPS, which is the one of important substance in cigarette. Investigators will measure TLR2 and TLR4 expression in lung tissue of patients whose lung will be resected. Investigators will compare the level of expression between COPD patients and healthy smokers.


Condition
Smoking
COPD

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Expression of TLR2 and TLR4 in the Lung of COPD Patients

Resource links provided by NLM:


Further study details as provided by Seoul National University Bundang Hospital:

Biospecimen Retention:   Samples Without DNA

Lung tissues are retained till the study ends.


Estimated Enrollment: 60
Study Start Date: October 2010
Estimated Study Completion Date: March 2012
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

All patients who will have lung resection for the therapeutic cause.

Criteria

Inclusion Criteria:

  • All patients who will have lung resection for the therapeutic cause.

Exclusion Criteria:

  • Patients who do not agree with our study protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01226199

Contacts
Contact: Sei Won Lee, MD 82 31 787 7053 seiwon@snubh.org

Locations
Korea, Republic of
Seoul National University Bundang Hospital Recruiting
Seongnam, Gyeongi, Korea, Republic of, 482 060
Contact: Sei Won Lee, MD    82 31 787 7053    seiwon@snubh.org   
Principal Investigator: Sei Won Lee, MD         
Sponsors and Collaborators
Seoul National University Bundang Hospital
  More Information

No publications provided

Responsible Party: Sei Won Lee/ Assistant Professor, Seoul National University Bundang Hospital
ClinicalTrials.gov Identifier: NCT01226199     History of Changes
Other Study ID Numbers: TLR2 and TLR4 in COPD tissue
Study First Received: October 21, 2010
Last Updated: June 7, 2011
Health Authority: South Korea: Korea Food and Drug Administration (KFDA)

Additional relevant MeSH terms:
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on November 20, 2014